A hipertónia mint kardiovaszkuláris kockázati tényező
Cikk címe: A hipertónia mint kardiovaszkuláris kockázati tényező
Szerzők: Dr. Alföldi Sándor
Intézmények: Fővárosi Önkormányzat Szent Imre Kórház
Évfolyam: VIII. évfolyam
Lapszám: 2009. / 04. lapszám
Oldal: 29-32
Rovat: EGÉSZSÉG - TÁRSADALOM, NÉPEGÉSZSÉGÜGY
Alrovat: EGÉSZSÉG – TÁRSADALOM
Absztrakt:
A hipertónia betegség a vezető haláloki tényező világszerte. Prevalenciája a fejlett országok felnőtt lakossága körében 35-55%. A megfelelő vérnyomás kontroll ugyanakkor még a fejlett országokban is mindössze 4065%. Mivel a hipertóniás betegek túlnyomó többségének további kardiovaszkuláris rizikófaktoraik is vannak, ezért hipertóniásokban nemcsak a vérnyomást, hanem az összes befolyásolható kardiovaszkuláris rizikófaktort kell egyidejűleg, lehetőleg fix-kombinációs készítményekkel kezelni, azaz előtérbe került egy új polypill stratégia.
Abstract:
Hypertension is the leading cause of global cardiovascular morbidity and mortality. The prevalence of high blood pressure is 35-55% in the adult population of developed countries and the proportion of well controlled hypertensive patients is not more than 40-65%. As the majority of individuals with hypertension tend to have more than one additional cardiovascular risk factor, not only the blood pressure, but every modifiable cardiovascular risk factor should also be simultaneously treated, possibly by fixed combination of drugs: a new polypill strategy is in focus.
VIII. évfolyam
2009. / 04. lapszám / Május
| Szerző | Intézmény |
|---|---|
| Dr. Alföldi Sándor | Fővárosi Önkormányzat Szent Imre Kórház |
[1] MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J.: Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335:765-774.
[2] Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913.
[3] European cardiovascular disease statistics, British Heart Foundation 2000 www.dphpc.ox.ac/UKbhfhprg.
[4] Kannel WB.: Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996; 275:1571-1576.
[5] Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J.: Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365:217-223.;
[6] Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, Kastarinen M, Poulter N, Primatesta P, Rodriguez-Artalejo F, Stegmayr B, Thamm M, Tuomilehto J, Vanuzzo D, Vescio F.: Hypertension prevalence and blood pressure levels in 6 European countries, Canada and the United States. JAMA 2003; 289:2363-2369.
[7] Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ, Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360:1347-1360.
[8] Franklin SS, Gustin W 4th, Wong ND, Larson MG, Weber MA, Kannel WB, Levy D.: Hemodynamic patterns of agerelated changes in blood pressure: the Framingham Heart Study. Circulation 1997;96:308-315.
[9] Multiple Risk Factor Intervention Trial Research Group Relationship between baseline risk factors and coronary heart disease and total mortality in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Prev Med 1986; 15: 254-273.
[10] Staessen JA, Gasowski J, Wang JG, Thijs L, Den Hond E, Boissel JP, Coope J, Ekbom T, Gueyffier F, Liu L, Kerlikowske K, Pocock S, Fagard RH.: Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355:865-872.
[11] Gasowski J, Fagard RH, Staessen JA, Grodzicki T, Pocock S, Boutitie F, Gueyffier F, Boissel JP, INDANA Project Collaborators.Pulsatile blood pressure component as predictor of mortality in hypertension: a metaanalysis of clinical trial control groups. J Hypertens 2002; 20:145-151.
[12] Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a
meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913.
[13] The Task Force for the Management of Arterial Hypertension of the ESH and of the ESC. 2007 Guidelines for the Management of Arterial Hypertension. J Hypertens 2007, 25:1105-1187.
[14] A Magyar Hypertonia Társaság Szakmai Irányelvek Bizottsága. A hypertoniabetegség felnőttkori és gyermekkori kezelésének szakmai és szervezeti irányelvei. Szerk: Kiss I, Hypertonia és Nephrologia 2008, 12: (Suppl 2): 85-154.
[15] Kannel WB.: Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 2000; 13 (Suppl 1):S3-S10.
[16] Assmann G, Schulte H.: The Prospective Cardiovascular Munster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J 1988; 116:1713-1724.
[17] Mancia G, Facchetti R, Bombelli M, Friz HP, Grassi G, Giannattasio C, Sega R.: Relationship of office, home, and ambulatory blood pressure to blood glucose and lipid variables in the PAMELA population. Hypertension 2005; 45:1072-1077.
[18] Multiple Risk Factor Intervention Trial Research Group Relationship between baseline risk factors and coronary heart disease and total mortality in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Prev Med 1986; 15: 254-273.
[19] Isles CG, Walker LM, Beevers GD et al.: Mortality in patients of the Glasgow Blood Pressure Clinic. J Hypertension, 1986; 4: 141-156.
[20] Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med. 2007; 167:141-147.
[21] Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with valsartan- or amlodipine-based regimens: VALUE, a randomised trial. Lancet, 2004, 363: 2022-31.
[22] Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL, for the Atherosclerosis Risk in Communities Study. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000; 342:905-912.
[23] Opie LH, Schall R.: Old antihypertensive and new diabetes. J Hypertens, 2004; 22:1453-1458.
[24] Messerli FH, Grossman E, Leonetti G.: Antihypertensive therapy and new onset diabetes. J Hypertens 2004; 22:1845-1847.
[25] Skarfors ET, Selinus KI, Lithell HO: Risk factors for developing non-insulin dependent diabetes: a 10 year follow up of men in Uppsala, BMJ. 1991;303(6805):755-60.
[26] Dunder K, Lind L, Zethelius B, et al.: Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study. BMJ. 2003;326(7391):681.
[27] Davey Smith G, Bracha Y, Svendsen KH, Neaton JD, Haffner SM, Kuller LH.: Incidence of type 2 diabetes in the randomized multiple risk factor intervention trial. Ann Intern Med 2005; 142:313-322.
[28] Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L, et al.: Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43:963-969.
[29] Zanchetti A, Ruilope LM.: Antihypertensive treatment in patients with type-2 diabetes mellitus: what guidance from recent controlled randomized trials? J Hypertens 2002; 20:2099-2110.
[30] Dahlöf B on behalf of the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding endroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.
[31] Jamerson KA, on behalf of the ACCOMPLISH investigators. Avoiding cardiovascular events in combination therapy in patients living with systolic hypertension. N Engl J Med 2008;359:2417-28.
[32] Mancia G.: Cardiovascular risk profile and blood pressure control in Italian hypertensive patients under specialist care. J Hypertens 2004;22:51(57.
[33] Yusuf S, Hawken S, Ounpuus S et al.: Effect of potentially modifiabel risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet, 2004;364:937-952.
[34] Sever, P, Dahlöf B, Poulter N on behalf of the ASCOT Steering Committee Members. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. European Heart J, 2006; 27:2982-2988.